1: Malouin F, Blais J, Chamberland S, Hoang M, Park C, Chan C, Mathias K, Hakem S, Dupree K, Liu E, Nguyen T, Dudley MN. RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases. Antimicrob Agents Chemother. 2003 Feb;47(2):658-64. doi: 10.1128/AAC.47.2.658-664.2003. PMID: 12543674; PMCID: PMC151748. 2: Griffith DC, Harford L, Williams R, Lee VJ, Dudley MN. In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria. Antimicrob Agents Chemother. 2003 Jan;47(1):43-7. doi: 10.1128/AAC.47.1.43-47.2003. PMID: 12499167; PMCID: PMC149000. 3: Griffith DC, Rodriguez D, Corcoran E, Dudley MN. Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother. 2008 Jan;52(1):244-7. doi: 10.1128/AAC.00776-07. Epub 2007 Oct 22. PMID: 17954697; PMCID: PMC2223871. 4: Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria. Antimicrob Agents Chemother. 2001 May;45(5):1422-30. doi: 10.1128/AAC.45.5.1422-1430.2001. PMID: 11302805; PMCID: PMC90483. 5: Johnson AP, Warner M, Carter M, Livermore DM. In vitro activity of cephalosporin RWJ-54428 (MC-02479) against multidrug-resistant gram-positive cocci. Antimicrob Agents Chemother. 2002 Feb;46(2):321-6. doi: 10.1128/AAC.46.2.321-326.2002. PMID: 11796337; PMCID: PMC127043. 6: Hecker SJ, Glinka TW, Cho A, Zhang ZJ, Price ME, Chamberland S, Griffith D, Lee VJ. Discovery of RWJ-54428 (MC-02,479), a new cephalosporin active against resistant gram-positive bacteria. J Antibiot (Tokyo). 2000 Nov;53(11):1272-81. doi: 10.7164/antibiotics.53.1272. PMID: 11213288. 7: Swenson JM, Tenover FC. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide- intermediate Staphylococcus aureus. J Antimicrob Chemother. 2002 May;49(5):845-50. doi: 10.1093/jac/dkf020. PMID: 12003982. 8: Lee VJ, Hecker SJ. Antibiotic resistance versus small molecules, the chemical evolution. Med Res Rev. 1999 Nov;19(6):521-42. doi: 10.1002/(sici)1098-1128(199911)19:6<521::aid-med4>3.0.co;2-9. PMID: 10557368. 9: Hoffman-Roberts HL, C Babcock E, Mitropoulos IF. Investigational new drugs for the treatment of resistant pneumococcal infections. Expert Opin Investig Drugs. 2005 Aug;14(8):973-95. doi: 10.1517/13543784.14.8.973. PMID: 16050791. 10: Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. In vitro anti-anaerobic activity of the cephalosporin derivative RWJ 54428, compared to seven other compounds. Clin Microbiol Infect. 2002 Dec;8(12):814-22. doi: 10.1046/j.1469-0691.2002.00475.x. PMID: 12519357.

C20H20CLN7O5S4

602.11

601.01

C, 39.90; H, 3.35; Cl, 5.89; N, 16.28; O, 13.29; S, 21.30

189448-35-9

9873517

Solid powder

3.04

5

14

10

37

975

2

NCCSCC1C=NC=CC=1SC1CSC2C(C(=O)N2C=1C(=O)O)NC(/C(/C1N=C(N)SC=1Cl)=N/O)=O

LTUWUNMGTLOPNC-RLQAYIIJSA-N

InChI=1S/C20H20ClN7O5S4/c21-15-11(26-20(23)37-15)12(27-33)16(29)25-13-17(30)28-14(19(31)32)10(7-35-18(13)28)36-9-1-3-24-5-8(9)6-34-4-2-22/h1,3,5,13,18,33H,2,4,6-7,22H2,(H2,23,26)(H,25,29)(H,31,32)/b27-12-/t13-,18-/m1/s1

5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-5-chloro-4-thiazolyl)(hydroxyimino)acetyl)amino)-3-((3-(((2-aminoethyl)thio)methyl)-4-pyridinyl)thio)-8-oxo-, (6R-(6alpha,7beta(Z)))-

RWJ-54428; RWJ 54428; RWJ54428; MC02479; MC-02479; MC 02479

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)